Clinical application and potential pluripotent effects of hepatocyte growth factor in spinal cord injury regeneration

References

• Quadri SA, Farooqui M, Ikram A, et al. Recent update on basic mechanisms of spinal cord injury. Neurosurg Rev. 2020;43(2):425–441. doi: 10.1007/s10143-018-1008-3
   PubMed Web of Science ®Google Scholar
• Nishimura S, Yasuda A, Iwai H, et al. Time-dependent changes in the microenvironment of injured spinal cord affects the therapeutic potential of neural stem cell transplantation for spinal cord injury. Mol Brain. 2013;6(1):3. doi: 10.1186/1756-6606-6-3
   PubMedGoogle Scholar
• Hashimoto S, Nagoshi N, Shinozaki M, et al. Microenvironmental modulation in tandem with human stem cell transplantation enhances functional recovery after chronic complete spinal cord injury. Biomaterials. 2023;295:122002. doi: 10.1016/j.biomaterials.2023.122002
   PubMed Web of Science ®Google Scholar
• Bracken MB, Shepard MJ, Collins WF, et al. A randomized controlled trial of methylprednisolone or naloxone in the treatment of acute spinal cord injury: results of the second national acute spinal cord injury study. N Engl J Med. 1990;322(20):1405–1411. doi: 10.1056/NEJM199005173222001
   PubMed Web of Science ®Google Scholar
• Bracken MB, Shepard MF, et al. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury: results of the third national acute spinal injury randomized controlled trial. JAMA. 1997;277(20):1597–1604. doi: 10.1001/jama.1997.03540440031029
   PubMed Web of Science ®Google Scholar
• Polland ME, Apple DF. Factors associated with improved neurologic outcomes in patients with incomplete tetraplegia. Spine. 2003;28(1):33–39. doi: 10.1097/00007632-200301010-00009
   PubMed Web of Science ®Google Scholar
• Hurlbert RJ. Methylprednisolone for acute spinal cord injury: an inappropriate standard of care. J Neurosurg. 2000;93(1):1–7. doi: 10.3171/spi.2000.93.1.0001
   PubMed Web of Science ®Google Scholar
• Pointillart V, Petitjean ME, Wiart L, et al. Pharmacological therapy of spinal cord injury during the acute phase. Spinal Cord. 2000;38(2):71–76. doi: 10.1038/sj.sc.3100962
   PubMed Web of Science ®Google Scholar
• Nakamura T, Shinno H, Ichihara A. Insulin and glucagon as a new regulator system for tryptophan oxygenase activity demonstrated in primary cultured rat hepatocytes. J Biol Chem. 1980;255(16):7533–7535. doi: 10.1016/S0021-9258(19)43858-1
   PubMed Web of Science ®Google Scholar
• Nakamura T, Tomita Y, Ichihara A. Density-dependent growth control of adult rat hepatocytes in primary culture. J Biochem. 1983;94(4):1029–1035. doi: 10.1093/oxfordjournals.jbchem.a134444
   PubMed Web of Science ®Google Scholar
• Forte TM. Primary hepatocytes in monolayer culture: a model for studies on lipoprotein metabolism. Annu Rev Physiol. 1984;46(1):403–415. doi: 10.1146/annurev.ph.46.030184.002155
   PubMedGoogle Scholar
• Nakamura T, Teramoto H, Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc Natl Acad Sci, USA. 1986;83(17):6489–6493. doi: 10.1073/pnas.83.17.6489
   PubMed Web of Science ®Google Scholar
• Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991;251(4995):802–804. doi: 10.1126/science.1846706
   PubMed Web of Science ®Google Scholar
• Nakamura T, Nawa K, Ichihara A, et al. Purification and subunit structure of hepatocyte growth factor from rat platelets. FEBS Lett. 1987;224(2):311–316. doi: 10.1016/0014-5793(87)80475-1
   PubMed Web of Science ®Google Scholar
• Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(6):588–610. doi: 10.2183/pjab.86.588
   PubMed Web of Science ®Google Scholar
• Funakoshi H, Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications.Clin Chim Acta. Clinica Chimica Acta. 2003;327(1–2):1–23. doi: 10.1016/S0009-8981(02)00302-9
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Tashiro K, Nakamura T. Marked increase of HGF mRNA in non-parenchymal liver cells of rats treated with hepatotoxins. Biochem Biophys Res Commun. 1989;165(3):1229–1234. doi: 10.1016/0006-291X(89)92733-2
   PubMed Web of Science ®Google Scholar
• Kitamura K, Fujiyoshi K, Yamane J-I, et al. Human hepatocyte growth factor promotes functional recovery in primates after spinal cord injury. PLoS One. 2011;6(11):e27706. doi: 10.1371/journal.pone.0027706
   PubMed Web of Science ®Google Scholar
• Kitamura K, Nagoshi N, Tsuji O, et al. Application of hepatocyte growth factor for acute spinal cord injury: the road from basic studies to human treatment. Int J Mol Sci. 2019;20(5):1054. doi: 10.3390/ijms20051054
   PubMed Web of Science ®Google Scholar
• Jeong SR, Kwon MJ, Lee HG, et al. Hepatocyte growth factor reduces astrocytic scar formation and promotes axonal growth beyond glial scars after spinal cord injury. Exp Neurol. 2012;233(1):312–322. doi: 10.1016/j.expneurol.2011.10.021
   PubMed Web of Science ®Google Scholar
• Yamane K, Mazaki T, Shiozaki Y, et al. Collagen-binding hepatocyte growth factor (HGF) alone or with a gelatin- furfurylamine hydrogel enhances functional recovery in mice after spinal cord injury. Sci Rep. 2018;8(1):917. doi: 10.1038/s41598-018-19316-y
   PubMed Web of Science ®Google Scholar
• Giannopoulou M, Dai C, Tan X, et al. Hepatocyte growth factor exerts its anti-inflammatory action by disrupting nuclear factor-κB signaling. The American Journal Of Pathology. 2008;173(1):30–41. doi: 10.2353/ajpath.2008.070583
   PubMed Web of Science ®Google Scholar
• Misawa H, Takigawa T, Takigawa T, et al. Multipotent neurotrophic effects of hepatocyte growth factor in spinal cord injury. IJMS. 2019;20(23):6078. doi: 10.3390/ijms20236078
   Google Scholar
• Benkhoucha M, Santiago-Raber ML, Schneiter G, et al. Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25 + Foxp3 + regulatory T cells. Proc Natl Acad Sci U S A. 2010;107(14):6424–6429. doi: 10.1073/pnas.0912437107
   PubMed Web of Science ®Google Scholar
• Nishimura S, Sasaki T, Shimizu A, et al. Global gene expression analysis following spinal cord injury in non-human primates. Exp Neurol. 2014;261:171–179. doi: 10.1016/j.expneurol.2014.05.021
   PubMed Web of Science ®Google Scholar
• Choi W, Lee J, Lee J, et al. Hepatocyte growth factor regulates macrophage transition to the M2 phenotype and promotes murine skeletal muscle regeneration. Front Physiol. 2019;10:914. doi: 10.3389/fphys.2019.00914
   PubMed Web of Science ®Google Scholar
• Akita H, Takagi N, Ishihara N, et al. Hepatocyte growth factor improves synaptic localization of the NMDA receptor and intracellular signaling after excitotoxic injury in cultured hippocampal neurons. Exp Neurol. 2008;210(1):83–94. doi: 10.1016/j.expneurol.2007.10.001
   PubMed Web of Science ®Google Scholar
• Ma TC, Campana A, Lange PS, et al. A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. J Neurosci. 2010;30(2):739–748. doi: 10.1523/JNEUROSCI.5266-09.2010
   PubMed Web of Science ®Google Scholar
• Huang HT, Sun ZG, Liu H-W, et al. ERK/MAPK and PI3K/AKT signal channels simultaneously activated in nerve cell and axon after facial nerve injury. Saudi Journal Of Biological Sciences. 2017;24(8):1853–1858. doi: 10.1016/j.sjbs.2017.11.027
   PubMed Web of Science ®Google Scholar
• Xu X, Fu S, Shi X, et al. Microglial BDNF, PI3K, and p-ERK in the Spinal Cord Are Suppressed by Pulsed Radiofrequency on Dorsal Root Ganglion to Ease SNI-Induced Neuropathic Pain in Rats. Pain Res Manag. 2019;2019:5948686. doi: 10.1155/2019/5948686
   PubMed Web of Science ®Google Scholar
• Yamane K, Misawa H, Takigawa T, et al. Multipotent neurotrophic effects of hepatocyte growth factor in spinal cord injury. Int J Mol Sci. 2019;20(23):6078. doi: 10.3390/ijms20236078
   PubMed Web of Science ®Google Scholar
• Liu C, Wu ZZ, Shu C-L, et al. Experimental investigation of HGF inhibiting glial scar in vitro. Cell Mol Neurobiol. 2011;31(2):259–268. doi: 10.1007/s10571-010-9616-7
   PubMed Web of Science ®Google Scholar
• Kitamura K, Iwanami A, Nakamura M, et al. Hepatocyte growth factor promotes endogenous repair and functional recovery after spinal cord injury. J Neurosci Res. 2007;85(11):2332–2342. doi: 10.1002/jnr.21372
   PubMed Web of Science ®Google Scholar
• Kitamura K, Iwanami A, Iwai, H et al. Therapeutic time window and preclinical efficacy of intrathecal administration of recombinant human hepatocyte growth factor for acute spinal cord injury. J Spine Res. 2016;7:934–939.
   Google Scholar
• Nagoshi N, Tsuji O, Kitamura K, et al. Phase I/II study of intrathecal administration of recombinant human hepatocyte growth factor in patients with acute spinal cord injury: a double-blind, randomized clinical trial of safety and efficacy. J Neurotrauma. 2020;37(15):1752–1758. doi: 10.1089/neu.2019.6854
   PubMed Web of Science ®Google Scholar
• Suematsu Y, Nagoshi N, Shinozaki M, et al. Hepatocyte growth factor pretreatment boosts functional recovery after spinal cord injury through human iPSC-derived neural stem/progenitor cell transplantation. Inflamm Regen. 2023;43(1):50. doi: 10.1186/s41232-023-00298-y
   PubMed Web of Science ®Google Scholar
• Hashimoto S, Nagoshi N, Nakamura M, et al. Regenerative medicine strategies for chronic complete spinal cord injury. Neural Regen Res. 2024;19(4):818–824. doi: 10.4103/1673-5374.382230
   PubMed Web of Science ®Google Scholar
• Wanner IB, Anderson MA, Song B, et al. Glial scar borders are formed by newly proliferated, elongated astrocytes that interact to corral inflammatory and fibrotic cells via STAT3-dependent mechanisms after spinal cord injury. J Neurosci. 2013;33(31):12870–12886. doi: 10.1523/JNEUROSCI.2121-13.2013
   PubMed Web of Science ®Google Scholar
• Dias DO, Kim H, Holl D, et al. Reducing pericyte-derived scarring promotes recovery after spinal cord injury. Cell. 2018;173(1):153–65 e22. doi: 10.1016/j.cell.2018.02.004
   PubMed Web of Science ®Google Scholar
• Gheradi E, Stoker M. Hepatocyte growth factor--scatter factor: mitogen, motogen, and met. Cancer Cells. 1991;3(6):227–232.
   PubMed Web of Science ®Google Scholar
• Matsumoto K, Nakamura T. Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions. Intl Journal Of Cancer. 2006;119(3):477–483. doi: 10.1002/ijc.21808
   PubMed Web of Science ®Google Scholar
• Morishita R, Aoki M, Hashiya N, et al. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension. 2004;44(2):203–209. doi: 10.1161/01.HYP.0000136394.08900.ed
   PubMed Web of Science ®Google Scholar
• Powell RJ, Simons M, Mendelsohn FO, et al. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008;118(1):58–65. doi: 10.1161/CIRCULATIONAHA.107.727347
   PubMed Web of Science ®Google Scholar
• Warita H, Kato M, Asada R, et al. Safety, tolerability, and pharmacodynamics of intrathecal injection of recombinant human HGF (KP-100) in subjects with amyotrophic lateral sclerosis: a phase I trial. J Clin Pharmacol. 2019;59(5):677–687. doi: 10.1002/jcph.1355
   PubMed Web of Science ®Google Scholar
• Hirano S, Kawamoto A, Tateya I, et al. A phase I/II exploratory clinical trial for intracordal injection of recombinant hepatocyte growth factor for vocal fold scar and sulcus. J Tissue Eng Regen Med. 2018;12(4):1031–1038. doi: 10.1002/term.2603
   PubMed Web of Science ®Google Scholar
• Cecchi F, Rabe DC, Bottaro DP. Targeting the HGF/Met signaling pathway in cancer therapy. Expert Opin Ther Targets. 2012;16(6):553–572. doi: 10.1517/14728222.2012.680957
   PubMed Web of Science ®Google Scholar
• Honmou O, Yamashita T, Morita T, et al. Intravenous infusion of auto serum-expanded autologous mesenchymal stem cells in spinal cord injury patients: 13 case series. Clin Neurol Neurosur. 2021;203:106565. doi: 10.1016/j.clineuro.2021.106565
   PubMed Web of Science ®Google Scholar
• Curtis E, Martin JR, Gabel B, et al. A first-in-human, phase i study of neural stem cell transplantation for chronic spinal cord injury. Cell Stem Cell. 2018;22(6):941–50 e6. doi: 10.1016/j.stem.2018.05.014
   PubMed Web of Science ®Google Scholar
• Sugai K, Sumida M, Shofuda T, et al. First-in-human clinical trial of transplantation of iPSC-derived NS/PCs in subacute complete spinal cord injury: Study protocol. Regen Ther. 2021;18:321–333. doi: 10.1016/j.reth.2021.08.005
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Moghaddamjou A, Harrop JS, et al. Safety and efficacy of riluzole in acute spinal cord injury study (RISCIS): a multi-center, randomized, placebo-controlled, double-blinded trial. J Neurotrauma. 2023;40(17–18):1878–1888. doi: 10.1089/neu.2023.0163
   PubMed Web of Science ®Google Scholar
• Fehlings MG, Kim KD, Aarabi B, et al. Rho inhibitor VX-210 in acute traumatic subaxial cervical spinal cord injury: design of the SPinal cord injury rho INhibition InvestiGation (SPRING) clinical trial. J Neurotrauma. 2018;35(9):1049–1056. doi: 10.1089/neu.2017.5434
   PubMed Web of Science ®Google Scholar
• Petitjean ME, Pointillart V, Dixmerias F, et al. Traitement médicamenteux de la lésion médullaire traumatique au stade aigu. Annales Françaises d’Anesthésie et de Réanimation. 1998;17(2):114–122. doi: 10.1016/S0750-7658(98)80058-0
   PubMedGoogle Scholar
• Cardenas DD, Ditunno J, Graziani V, et al. Phase 2 trial of sustained-release fampridine in chronic spinal cord injury. Spinal Cord. 2007;45(2):158–168. doi: 10.1038/sj.sc.3101947
   PubMed Web of Science ®Google Scholar
• Geisler FH, Coleman WP, Grieco G, Poonian D. Sygen Study Group. The Sygen multicenter acute spinal cord injury study. Spine (Phila Pa 1976). 2001;26(24 Suppl):87–98. doi: 10.1097/00007632-200112151-00015
   PubMed Web of Science ®Google Scholar
• Wu JC, Huang WC, Tsai Y-A, et al. Nerve repair using acidic fibroblast growth factor in human cervical spinal cord injury: a preliminary phase I clinical study. J Neurosurg Spine. 2008;8(3):208–214. doi: 10.3171/SPI/2008/8/3/208
   PubMed Web of Science ®Google Scholar
• Koda M, Hanaoka H, Sato T, et al. Study protocol for the G-SPIRIT trial: a randomised, placebo-controlled, double-blinded phase III trial of granulocyte colony-stimulating factor-mediated neuroprotection for acute spinal cord injury. BMJ Open. 2018;8(5):e019083. doi: 10.1136/bmjopen-2017-019083
   PubMed Web of Science ®Google Scholar
• Alstermark B, Isa T, Ohki Y, et al. Disynaptic Pyramidal Excitation in Forelimb Motoneurons Mediated Via C 3 –C 4 Propriospinal Neurons in the Macaca fuscata. Journal Of Neurophysiology. 2004;6(6):3580–3585. doi: 10.1152/jn.1999.82.6.3580
   Google Scholar
• Alstermark B, Ogawa J, Ohki Y, et al. Disynaptic pyramidal excitation in forelimb motoneurons mediated via C 3 –C 4 propriospinal neurons in the Macaca fuscata. Journal Of Neurophysiology. 1999;82(6):3580–3585. doi: 10.1152/jn.1999.82.6.3580
   PubMed Web of Science ®Google Scholar
• Tillakaratne NJ, Guu JJ, de Leon RD, et al. Functional recovery of stepping in rats after a complete neonatal spinal cord transection is not due to regrowth across the lesion site. Neuroscience. 2010;166(1):23–33. doi: 10.1016/j.neuroscience.2009.12.010
   PubMed Web of Science ®Google Scholar
• Potas JR, Zheng C, Moussa C, et al. Augmented locomotor recovery after spinal cord injury in the athymic nude rat. Journal Of Neurotrauma. 2006;23(5):660–673. doi: 10.1089/neu.2006.23.660
   PubMed Web of Science ®Google Scholar
• Kirshblum S, Snider B, Eren F, et al. Characterizing natural recovery after traumatic spinal cord injury. J Neurotrauma. 2021;38(9):1267–1284. doi: 10.1089/neu.2020.7473
   PubMed Web of Science ®Google Scholar